• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1266606 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
. T( V" O8 e! m: R) ONOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
0 A1 B5 E9 R/ T, }- P# P+ Author Affiliations
. A% F& p1 L% Q$ o: D7 @0 J; H) K# e
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ' ^, \4 y, P9 b3 c
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) [! a( [# A2 \0 o; p: O. K
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' m. a& _3 ^1 j8 k! e+ f, u
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ' E9 a! M5 F/ G# X8 w5 a. ^. b2 O! J
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan   W5 ~# I4 ]3 U- z+ }! J  p5 D
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
" Q! o1 g" q7 _7Kinki University School of Medicine, Osaka 589-8511, Japan 2 {% R' P, P7 z, o" u9 w
8Izumi Municipal Hospital, Osaka 594-0071, Japan + N! h0 o! ~1 M( t+ C& B
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 4 R  k/ \3 [% k+ o# x
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp # N+ b: V9 J; s8 G8 P
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ; f' \  f/ y7 t' z

% h$ E8 r9 l0 ^$ V% D3 r+ w
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
8 t7 r/ j0 m% e1 p* M7 G: z+ Q
0 i2 I: T1 j: y! a: qAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
8 D# D4 n7 N0 U$ G
" M/ O3 ?% {& o5 RAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
3 R1 y- O' Y9 q& N  B2 _
4 M, B0 v% g* j$ [8 R, ?Published online on: Thursday, December 1, 2011 ) o9 k. x0 o6 E
' V1 ?  d4 |7 V4 O# u1 z
Doi: 10.3892/ol.2011.507
0 I0 s. B' n' K# u, ?
/ S: S9 D; D0 i" h/ I: P4 F0 r) [Pages: 405-410
' S) |" X( u$ C4 ~& y4 n) j. Q! f; k5 A! L
Abstract:
* h) }5 R. p  u, M# M6 B" Q0 V1 uS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.! n& b2 ]7 Y2 e
; Q' R' m# y8 A6 g3 @/ ~$ S! M
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population' L' T: U  v; E8 k+ a
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
: F; A7 i9 P% n. M+ Author Affiliations
3 v# @* S( ~& u. p  @+ a- c1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 5 {5 P, W2 x1 G  m
2Department of Thoracic Surgery, Kyoto University, Kyoto
, `! |! V7 z# e" P3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
- S# f7 t, O  g6 v, o( z2 K&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 5 J# w0 O: K& d8 D+ I/ H
Received September 3, 2010.
: S( S; B2 y4 Q8 FRevision received November 11, 2010. ; D' d  e1 y# d" G; M1 Q
Accepted November 17, 2010. 6 G' G% f9 N- M  Z6 }
Abstract0 Y5 w4 N, M% u* G7 M
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. , C# ~% y* z% a" F
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
9 _& z& H1 N/ n1 K! U; SResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
- S, U( E" ]  M& Z; }/ j7 yConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. # M  D4 k9 ?3 T0 \3 ]/ |  w4 v
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。' v$ r1 s- E, L: Q
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
# \% Z$ p# B4 `, m+ F
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy! T  g. n) k+ ~! I
http://clinicaltrials.gov/ct2/show/NCT01523587
$ m7 \( c, X* w) h0 p4 H6 _! t
" B9 b; D- c2 E9 Z" tBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC0 d3 ]' D$ W- y0 I) \
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 ' Y3 C0 E% `: C. ]/ B' ?

7 V- s5 i9 j- p从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。* h+ q! I1 F6 Y/ B# x
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
9 L, ^' O! Z: N: u从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。- `4 \' H  T& ]. {  @
至今为止,未出 ...
/ ~" _4 D/ a0 [! Q2 q% N& U& U+ X
没有副作用是第一追求,效果显著是第二追求。
! N& x6 b  |3 H+ U+ z, a# Y% H不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表